Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ticagrelor Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial

Next Previous
Trial Profile

Ticagrelor Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms PL-PLATELET

Most Recent Events

  • 25 Mar 2021 Status changed from recruiting to suspended, because competitive studies were conducted at the same time.
  • 12 Sep 2017 Status changed from not yet recruiting to recruiting.
  • 11 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top